Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Review

Autoantibody profiling for the study and treatment of autoimmune disease

Wolfgang Hueber1, Paul J Utz13, Lawrence Steinman23 and William H Robinson123*

Author Affiliations

1 Department of Medicine, Division of Rheumatology and Immunology, Stanford University School of Medicine, Stanford, California, USA

2 Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA

3 Tolerion, Palo Alto, California, USA

For all author emails, please log on.

Arthritis Res 2002, 4:290-295  doi:10.1186/ar426

Published: 7 May 2002

Abstract

Proteomics technologies enable profiling of autoantibody responses using biological fluids derived from patients with autoimmune disease. They provide a powerful tool to characterize autoreactive B-cell responses in diseases including rheumatoid arthritis, multiple sclerosis, autoimmune diabetes, and systemic lupus erythematosus. Autoantibody profiling may serve purposes including classification of individual patients and subsets of patients based on their 'autoantibody fingerprint', examination of epitope spreading and antibody isotype usage, discovery and characterization of candidate autoantigens, and tailoring antigen-specific therapy. In the coming decades, proteomics technologies will broaden our understanding of the underlying mechanisms of and will further our ability to diagnose, prognosticate and treat autoimmune disease.

Keywords:
autoantibodies; autoimmune disease; proteomics; protein arrays